Lupin has launched Methylergonovine Maleate tablets, used for the prevention and control of postpartum hemorrhage, in the American market.
The company said in a statement that it has launched the product after having earlier received approval from the US Food and Drug Administration (USFDA).
Lupin’s product is the generic equivalent of Novartis Pharmaceuticals Corp’s Methergine which is indicated for the prevention and control of postpartum hemorrhage. As per the latest industry estimates, Methylergonovine Maleate tablets had annual sales of around $71.5 million in the US.
Lupin shares were trading 1.18 per cent up at Rs 772.10 on the BSE.